posted on 2020-11-11, 21:31authored byStephen
E. Miller, Kohei Tsuji, Rachel P.M. Abrams, Terrence R. Burke, Joel P. Schneider
Here,
we describe the use of peptide backbone N-methylation
as a new strategy to transform membrane-lytic peptides
(MLPs) into cytocompatible intracellular delivery vehicles. The ability
of lytic peptides to engage with cell membranes has been exploited
for drug delivery to carry impermeable cargo into cells, but their
inherent toxicity results in narrow therapeutic windows that limit
their clinical translation. For most linear MLPs, a prerequisite for
membrane activity is their folding at cell surfaces. Modification
of their backbone with N-methyl amides inhibits folding,
which directly correlates to a reduction in lytic potential but only
minimally affects cell entry. We synthesized a library of N-methylated peptides derived from MLPs and conducted structure–activity
studies that demonstrated the broad utility of this approach across
different secondary structures, including both β-sheet and helix-forming
peptides. Our strategy is highlighted by the delivery of a notoriously
difficult class of protein–protein interaction inhibitors that
displayed on-target activity within cells.